A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia



Status:Recruiting
Conditions:Blood Cancer, Lymphoma
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:4/6/2019
Start Date:November 5, 2018
End Date:October 2025
Contact:Jason Paik, MD, PhD
Email:clinicaltrials@beigene.com
Phone:1-877-828-5568

Use our guide to learn which trials are right for you!

A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

This study is designed to compare the overall response rate of zanubrutinib versus ibrutinib
in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic
lymphoma.

This is a global, Phase 3, randomized study of zanubrutinib versus ibrutinib in approximately
400 patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic
lymphoma.

The primary efficacy endpoint is overall response rate determined by independent central
review. Patients will be randomized in a 1:1 manner to either zanubrutinib or ibrutinib.
Treatment with zanubrutinib and ibrutinib will be open label.

Inclusion Criteria

1. Age 18 years or older

2. Confirmed diagnosis of CLL or SLL that meets the 2008 IWCLL criteria

3. CLL/SLL requiring treatment per 2008 IWCLL criteria

4. Relapsed or refractory to at least 1 prior systemic therapy for CLL/SLL

5. Measurable disease by CT/magnetic resonance imaging (MRI)

6. ECOG performance status of 0, 1, or 2

7. Life expectancy ≥ 6 months

8. Adequate bone marrow function

9. Adequate renal and hepatic function

Exclusion Criteria

1. Known prolymphocytic leukemia or history of, or currently suspected, Richter's
transformation

2. Clinically significant cardiovascular disease.

3. Prior malignancy within the past 3 years, except for curatively treated basal or
squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the
cervix or breast

4. History of severe bleeding disorder or history of spontaneous bleeding requiring blood
transfusion or other medical intervention

5. History of stroke or intracranial hemorrhage within 180 days before first dose of
study drug

6. Severe or debilitating pulmonary disease

7. Active fungal, bacterial, and/or viral infection requiring systemic therapy

8. Known central nervous system involvement by leukemia or lymphoma

9. Known infection with HIV or active viral hepatitis B or C infection

10. Moderate or severe hepatic impairment, ie, Child-Pugh class B or C

11. Major surgery within 4 weeks of the first dose of study drug

12. Prior treatment with a BTK inhibitor

13. Toxicity from prior anticancer therapy that has not recovered to ≤ Grade 1

14. Pregnant or lactating women

15. Vaccination with a live vaccine within 35 days prior to the first dose of study drug

16. Hypersensitivity to zanubrutinib, ibrutinib, or any of the other ingredients in either
drug

17. Concurrent participation in another therapeutic clinical trial
We found this trial at
10
sites
Lake Success, New York 11042
Principal Investigator: Morton Coleman, MD
?
mi
from
Lake Success, NY
Click here to add this to my saved trials
825 Eastlake Ave E
Seattle, Washington 98109
(206) 288-7222
Principal Investigator: Mazyar Shadman, MD
Seattle Cancer Care Alliance Seattle Cancer Care Alliance (SCCA) is a cancer treatment center that...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Brick, New Jersey 08724
Principal Investigator: Apurv Agrawal, MD
?
mi
from
Brick, NJ
Click here to add this to my saved trials
Florham Park, New Jersey 07932
Principal Investigator: Benjamin Freeman, MD
?
mi
from
Florham Park, NJ
Click here to add this to my saved trials
Frankston,
Principal Investigator: Patricia Walker, MD
?
mi
from
Frankston,
Click here to add this to my saved trials
400 North Stephanie Street
Las Vegas, Nevada 89014
Principal Investigator: Edwin Kingsley, MD
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Lubbock, Texas 79410
Principal Investigator: Donald Quick, MD
?
mi
from
Lubbock, TX
Click here to add this to my saved trials
Roanoke, Virginia 24014
Principal Investigator: Amanda Twardy, MD
?
mi
from
Roanoke, VA
Click here to add this to my saved trials
Seattle, Washington 98108
Principal Investigator: Solomon Graf, MD
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Spokane, Washington 99208
Principal Investigator: Arvind Chaudhry
?
mi
from
Spokane, WA
Click here to add this to my saved trials